5 Key Takeaways
-
1
The PRIMAvera trial enrolled 38 patients with geographic atrophy at 17 centers across Europe.
-
2
The PRIMA system uses camera-equipped glasses to project signals to a subretinal photovoltaic implant, which stimulates surviving retinal cells.
-
3
Among 18 patients evaluated at 3 years, average vision with the device improved from roughly 20/460 at baseline to about 20/120.
-
4
At 3 years, 14 of 18 patients (78%) improved by at least 2 lines, and the same proportion improved by at least 3 lines.
-
5
With the device switched off, vision in implanted eyes remained essentially unchanged over 3 years; 3 patients had a serious eye-related adverse event between months 13 and 36.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.